|Bid||48.31 x 900|
|Ask||48.32 x 1100|
|Day's Range||48.23 - 48.78|
|52 Week Range||37.47 - 49.78|
|Beta (3Y Monthly)||0.97|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Hologic, Inc. announced today that the Company plans to release its financial results for the third quarter of fiscal 2019 on Wednesday, July 31, 2019, after the market closes.
Hologic, Inc. (HOLX), a global leader in women’s health, announced today that it has made a binding offer to acquire (directly or through an affiliate) SuperSonic Imagine (Euronext: SSI, FR0010526814), a France-based innovator in cart-based ultrasound products, and that it has entered into an exclusive negotiation agreement with the company and its main shareholders toward that end. “Like our previous acquisitions of Faxitron and Focal, acquiring SuperSonic Imagine will strengthen our strategy to provide comprehensive screening, interventional and surgical solutions across the continuum of breast health care,” said Pete Valenti, Hologic’s Division President, Breast and Skeletal Health Solutions. Under the terms of the binding offer, Hologic has agreed to acquire SuperSonic Imagine’s outstanding shares at a price of €1.50 per share.
Company’s Costa Rica and Danbury, CT manufacturing facilities recognized for energy savings and operational efficiency initiatives
Hologic, Inc. (HOLX) announced today that it has signed an agreement with DEXA+ to distribute Hologic’s Horizon® DXA system for body composition measurement. With over 20 years of experience, DEXA+ works with healthcare practices nationwide to implement and optimize DXA technology to grow integrative medicine, health and wellness programs. The partnership allows Hologic to expand its expertise in body composition assessment and the reach of its market-leading DXA system.
--Improved accuracy in identifying bacterial vaginosis , vulvovaginal candidiasis and trichomoniasis will enable more target
Company to host timely educational panel on breast density featuring leading clinicians
Hologic, Inc. (HOLX) will showcase its growing breast surgery franchise, which includes products such as the new Trident® HD specimen radiography system, LOCalizer™ wire-free guidance system and the BioZorb® marker, in Booth #103 at the 20th Annual Meeting of The American Society of Breast Surgeons (ASBS) in Dallas from April 30 to May 5. The pioneer behind the Genius™ 3D Mammography™ exam, Hologic has recently expanded its product portfolio significantly through insight-driven innovation and strategic acquisitions to address the entire clinical continuum of breast cancer diagnosis and care.
The Trident products are the only specimen radiographs on the market to use amorphous selenium direct capture imaging – the same detector technology used in Hologic’s 3Dimensions™ mammography system – to generate crisp, clear, high-resolution images. “The Trident HD system is a breakthrough solution that delivers the superior image quality clinicians have come to expect from Hologic products, helping to streamline workflows and reduce recalls while decreasing procedure times,” said Pete Valenti, Hologic’s Division President, Breast and Skeletal Health Solutions.
Cynosure launches “Be strong. Hologic’s (Nasdaq: HOLX) Cynosure division announced today that iconic actress, model, Broadway star and author Brooke Shields will serve as national spokesperson for the state-of-the-art SculpSure® body contouring laser treatment. Be confident.” campaign, Shields will inspire consumers to live confidently in a body that reflects their hard work and commitment to a healthy lifestyle.
Hologic, Inc. announced today that the Company plans to release its financial results for the second quarter of fiscal 2019 on Wednesday, May 1, 2019, after the market closes.
Proposed rule highlights the risks of breast density and emphasizes important advances in mammography technology, including 3D mammography
Hologic, Inc. (HOLX), an innovative medical technology company focused on improving women’s health and well-being through early detection and treatment, today opened its first Learning and Experience Centre in Zaventem, Belgium (a municipality neighboring Brussels). The state-of-the-art facility provides comprehensive training for customers, healthcare professionals and employees across Hologic’s Europe, Middle East and Africa (EMEA) region, centralizing the education experience for Hologic’s technologies.
NEW YORK, March 05, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Hologic, Inc. (HOLX) announced today that it has received a CE mark in Europe for its Omni™ hysteroscope, an innovative three-in-one modular scope with advanced visualization capabilities designed for both diagnostic and therapeutic hysteroscopic procedures. Obstetricians and gynecologists (ObGyns) can use the new Omni hysteroscope in out- and in-patient settings. “Experts agree that direct visualization of the uterine cavity in women with abnormal uterine bleeding is the gold standard that allows ObGyns to accurately identify and collect quality samples and remove pathology – in a safer and more effective manner than blind biopsy and curettage,”1 said Edward Evantash, M.D., Medical Director and Vice President of Global Medical Affairs, Hologic.
Hologic, Inc. (HOLX) announced today that its Aptima® HIV-1 Quant Dx Assay has received two new CE marks in Europe – for early infant diagnosis (EID) and for testing dried blood spots (DBS). This means the assay can be used to qualitatively detect HIV-1 RNA as an aid in the diagnosis of HIV-1 infected infants under 18 months old, and to test an additional sample type (DBS) to monitor viral load and disease progression in HIV-1 infected individuals in European and African countries. It is the first and only dual-claim assay for both viral load and early infant diagnosis.
-- FDA clearance makes clinically validated assay available for sexually-transmitted infection listed as emerging threat by the CDC --
NEW YORK, Jan. 17, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Hologic, Inc. announced today that the Company plans to release its financial results for the first quarter of fiscal 2019 on Wednesday, January 30, 2019, after the market closes.
Hologic, Inc. (HOLX) announced today preliminary revenue results for its first fiscal quarter ended December 29, 2018. The Company expects to report total revenues of approximately $831 million, an increase of 5% compared to the prior year period, or 5.7% in constant currency.
Hologic, Inc. announced today that the Company will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 8, 2019 at 11:30 a.m.